WealthTrust Axiom LLC lifted its position in Eli Lilly And Co (NYSE:LLY) by 0.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,749 shares of the company’s stock after acquiring an additional 101 shares during the quarter. Eli Lilly And Co accounts for approximately 1.3% of WealthTrust Axiom LLC’s investment portfolio, making the stock its 24th largest holding. WealthTrust Axiom LLC’s holdings in Eli Lilly And Co were worth $3,095,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in LLY. FMR LLC increased its stake in shares of Eli Lilly And Co by 172.9% during the 2nd quarter. FMR LLC now owns 1,188,301 shares of the company’s stock worth $101,398,000 after purchasing an additional 752,864 shares during the last quarter. Douglass Winthrop Advisors LLC acquired a new position in shares of Eli Lilly And Co during the 3rd quarter worth about $373,000. Capital Investment Advisors LLC increased its stake in shares of Eli Lilly And Co by 6.0% during the 3rd quarter. Capital Investment Advisors LLC now owns 35,556 shares of the company’s stock worth $3,816,000 after purchasing an additional 2,018 shares during the last quarter. Stock Yards Bank & Trust Co. increased its stake in shares of Eli Lilly And Co by 41.5% during the 3rd quarter. Stock Yards Bank & Trust Co. now owns 54,399 shares of the company’s stock worth $5,837,000 after purchasing an additional 15,956 shares during the last quarter. Finally, First Hawaiian Bank acquired a new position in Eli Lilly And Co in the 3rd quarter valued at about $912,000. Hedge funds and other institutional investors own 80.84% of the company’s stock.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 195,000 shares of the stock in a transaction that occurred on Monday, November 19th. The shares were sold at an average price of $115.31, for a total transaction of $22,485,450.00. Following the transaction, the insider now owns 118,505,584 shares in the company, valued at approximately $13,664,878,891.04. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Myles O’neill sold 25,000 shares of the stock in a transaction that occurred on Monday, December 10th. The stock was sold at an average price of $112.92, for a total transaction of $2,823,000.00. Following the transaction, the senior vice president now owns 26,562 shares in the company, valued at approximately $2,999,381.04. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 817,843 shares of company stock worth $94,595,335. Company insiders own 0.11% of the company’s stock.

LLY has been the topic of a number of research reports. UBS Group decreased their price target on shares of Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating on the stock in a research note on Friday. TheStreet upgraded shares of Eli Lilly And Co from a “c+” rating to a “b+” rating in a research note on Tuesday, November 6th. Cantor Fitzgerald reiterated a “buy” rating and issued a $128.00 price target on shares of Eli Lilly And Co in a research note on Wednesday, October 17th. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $128.00 price target on the stock in a research note on Wednesday, November 28th. Finally, ValuEngine upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating in a research note on Monday, November 12th. Eleven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Eli Lilly And Co has a consensus rating of “Buy” and an average price target of $111.41.

Shares of NYSE:LLY traded down $2.38 on Monday, reaching $117.22. 1,743,701 shares of the company’s stock were exchanged, compared to its average volume of 5,609,386. Eli Lilly And Co has a twelve month low of $73.69 and a twelve month high of $121.84. The firm has a market cap of $125.67 billion, a PE ratio of 21.12, a PEG ratio of 1.91 and a beta of 0.37. The company has a quick ratio of 1.53, a current ratio of 1.91 and a debt-to-equity ratio of 0.83.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a return on equity of 42.55% and a net margin of 13.16%. The business had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. During the same quarter in the previous year, the company earned $1.14 EPS. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. On average, research analysts expect that Eli Lilly And Co will post 5.6 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be given a dividend of $0.645 per share. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.20%. The ex-dividend date of this dividend is Thursday, February 14th. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.56. Eli Lilly And Co’s dividend payout ratio is presently 40.54%.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/wealthtrust-axiom-llc-purchases-101-shares-of-eli-lilly-and-co-lly/2813095.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: Mutual Funds

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.